Iain MacLeod LL.M Ph.D

CEO and Chief Science Officer // Co-Founder

Iain is a co-founder and CEO of Aldatu Biosciences. Also serving as Chief Science Officer, Iain is responsible for leading the advancement of Aldatu’s pathogen and drug resistance diagnostic technology in addition to guiding the company’s global health strategy.

 

Prior to founding Aldatu Biosciences in 2014, Iain undertook his post-doctoral training at the Harvard TH Chan School of Public Health, and the Botswana-Harvard AIDS Institute in Gaborone, Botswana, where he focused on HIV drug resistance. Iain maintains an academic appointment at the Harvard TH Chan School of Public Health.

 

Iain holds a Ph.D. in Pathology – specializing in molecular virology – from the University of Cambridge (2008), an LL.M. in International Law, and a B.Sc. in Virology from the University of Glasgow.

Mike Henry

Chief Business Officer

As CBO, Mike leads dealmaking at Aldatu. Mike is a molecular diagnostics expert with over 20 years of senior leadership experience in biotechnology business development at Ancestry, Quest Diagnostics, Thermo Fisher, Athena Diagnostics and other life science companies, and in medical technology transfer at academic medical centers. He sold Athena to Quest for $740M in 2011. Mike is an advisor with biotech startups and a member of Berkeley Angel Network.

 

Mike holds an MBA and an MA Botany from University of California Berkeley and a BS Botany from University of Michigan.

Betsy Wonderly Trainor

VP Development

Betsy is responsible for commercialization strategy, NGO partnership strategy, and other development efforts. Betsy has over 10 years of experience working in emerging markets, focusing on the validation and implementation of infectious disease diagnostics. Prior to Aldatu, Betsy was the VP of Business Development at Daktari Diagnostics, an HIV diagnostics company. She also led the validation and implementation of Ebola diagnostics in West Africa on behaf of FIND (Foundation for Innovative New Diagnostics) in collaboration with the World Health Organization.

 

Betsy has a B.S in Human Development from Cornell University and is a graduate of the Product Management Program at Berkeley Haas School of Business.

Larry Carrasco

Director of Operations

Larry is responsible Lab Management, Operations, Finances, EH&S, HR functions, and day to day business requirements.

 

Larry has over 15 years of experience working in operations and laboratory management focusing on developing and deploying best practice laboratory support services.  Prior to Aldatu, Larry Held the roles of Program Manager and Regional Services Manager at Thermo Fisher Scientific, within their Unity Lab Services group.  He has also worked with EMD Serono in their Laboratory Support Group and Quest Diagnostics in their Cytology Department.

 

Larry has a Biotechnology Certificate from Boston University.

Maria Denaro

Technology Specialist

Maria joined Aldatu Biosciences in 2015 as Technology Specialist, taking on the development of multiplex PANDAA assays and daily lab management with earnest. She has many years experience as a biotech professional in the fields of xenotransplantation and gene therapy.

 

Prior to joining Aldatu, Maria was Technical Specialist in qPCR at bluebirdbio, Inc. She received a Bachelor of Science degree from Yale University – Go Bulldogs!

Haifa Ghandour

Lead Scientist, Product and Quality

Haifa joined Aldatu Biosciences in 2017 as a Lead Scientist, and is responsible for guiding in-vitro diagnostic (IVD) product validation and the company’s quality program. Prior to Aldatu, Haifa was a Group Leader at GnuBio, a Next Generation Sequencing (NGS) startup company. Haifa also led several integrated drug discovery programs aimed at identifying small molecules therapeutic targets at Albany Molecular Research, Inc.

 

Haifa holds B.Sc. in Biology, M.Sc. and Ph.D. in Medical Sciences from the Technion – Israel Institute of Technology, and has completed postdoctoral trainings at the USDA-HNRCA of Tufts University and the Pathology Department of Brigham’s and Women Hospital and Harvard Medical School.

John Rice

Lead Scientist, Assay Development

John joined Aldatu Biosciences in 2020 as a Lead Scientist, and is responsible for managing clinical diagnostic and product development for our expanding R&D pipeline. Prior to Aldatu, John was Senior Scientist at Thermagenix a PCR reagent and assay development startup company. John has over 15 years of experience with innovative diagnostic assays involving infectious disease genetics. He has numerous issued and pending patents for his work.

 

John obtained a M. Sc. in Genetics from Texas A&M University, and received a B.S. in Biology from University of Massachusetts/Boston.

Namita Wadke

Research Associate

Namita joined Aldatu Biosciences in 2019 as a research associate and has facilitated the development of multiplex PANDAA assays for HIV drug resistance genotyping. Prior to joining Aldatu, Namita worked at MIT on projects involving next-generation sequencing (NGS).

 

Namita is a graduate in molecular biology from the University of Skövde, Sweden. She has contributed to projects involving plant-microbe symbiosis at the Max Planck Institute for Chemical Ecology as part of a Jena School for Microbial Communication (JSMC) fellowship.

David Raiser Ph.D

Chairman of the Board // Co-Founder

As Chairman, David leads Aldatu’s Board of Directors. Prior to his appointment as Chairman, David served as Aldatu’s CEO from 2014 to 2020.

 

David holds a Ph.D in Genetics from Harvard Medical School, where his dissertation focused on stem cell biology and diseases of ribosome dysfunction. He also holds a BS in Biology and BA in Music from the University of Richmond.

Iain MacLeod LL.M Ph.D

CEO and Chief Science Officer // Co-Founder

Mike Henry

Chief Business Officer

Marta Fernández Suárez, Ph.D

Diagnostics R&D Expert and Consultant

Dr. Fernández Suárez has over 10 years of scientific and industry experience commercializing scientific technologies for developing markets.  Most recently, Marta served as VP of Assay, R&D at Daktari Diagnostics, a HIV diagnostic company, where she developed a complex immunoassay platform designed for point-of-care medical testing.  Prior to her role at Daktari, Dr. Fernández Suárez developed a point-of-care diagnostic for tuberculosis as a Postdoctoral Research fellow as Massachusetts General Hospital.

 

Marta obtained her Ph.D. in Biochemistry at the Massachusetts Institute of Technology (MIT), and received a B.S. in Chemistry and M.S. in Chemical Engineering at the Institut Quimic de Sarria (Barcelona, Spain).